Company intelligence / Profile preview

Cardiavent, Inc.

Ann Arbor, Michigan, United Stateszoominfo.com ↗

Ownership: Private
Employees: ~4
Development stage: Other

Overview

Cardiavent’s lead compound, CARD‑024—a novel vitamin D receptor activator—has demonstrated biologic activity without toxic hypercalcemia in preclinical and Phase 1 studies. The compound shows potential as a best-in-class treatment for hyperparathyroidism and hypertension. The company highlights a rapid development pathway attractive for pharmaceutical partnerships or acquisition

Therapeutic areas: EndocrinologyCardiovascularNephrology
Modalities: Small molecules (specifically vitamin D receptor activators)
Industry: Biotech

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed; the company notes its development pathway may be attractive for 'Big Pharma' partnering/acquisition but no specific deals are listed.

Beyond the preview

Go deeper on Cardiavent, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cardiavent, Inc..

Explore the full profile